Market Access News | pharmaphorum

News

Emergent Bio gets FDA green light for mpox vaccine

Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency b

News

J&J launches gMG market bid with nipocalimab filing

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete wit

News

GSK gets EU okay for RSV shot in younger age group

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could l

News

Lilly launches single-dose Zepbound to ease self-pay access

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford

News

Pfizer joins Lilly in direct-to-consumer drive

Pfizer has become the latest big pharma group to launch a web-based platform that opens up a direct-to-consumer channel for medicines access.

News

Pathogenic Acanthamoeba as seen under a light microscope

EU approves first therapy for acanthamoeba keratitis

The European Commission has approved SIFI's Akantior as the first therapy anywhere in the world for acanthamoeba keratitis (AK), an ultra-rare parasitic infection that can lead to blindness

Emergent Bio gets FDA green light for mpox vaccine

J&J launches gMG market bid with nipocalimab filing

GSK gets EU okay for RSV shot in younger age group

Lilly launches single-dose Zepbound to ease self-pay access

Pfizer joins Lilly in direct-to-consumer drive

EU approves first therapy for acanthamoeba keratitis

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks